Michallet, A. Et Al. 2018. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: Primary analysis of the randomized, open-label mable study. Haematologica , vol.103, no.4 , 698-706.

Michallet, A., Aktan, M., Hiddemann, W., İLHAN, ., Johansson, P., Laribi, K., ... Meddeb, B.(2018). Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: Primary analysis of the randomized, open-label mable study. Haematologica , vol.103, no.4, 698-706.

Michallet, Anne-Sophie Et Al. "Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: Primary analysis of the randomized, open-label mable study," Haematologica , vol.103, no.4, 698-706, 2018

Michallet, Anne-Sophie Et Al. "Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: Primary analysis of the randomized, open-label mable study." Haematologica , vol.103, no.4, pp.698-706, 2018

Michallet, A. Et Al. (2018) . "Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: Primary analysis of the randomized, open-label mable study." Haematologica , vol.103, no.4, pp.698-706.

@article{article, author={Anne-Sophie Michallet Et Al. }, title={Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: Primary analysis of the randomized, open-label mable study}, journal={Haematologica}, year=2018, pages={698-706} }